Study guide

2.2 Expanded Scope of Practice: Minor Ailments Prescribing, Renewals & Injections

PEBC Pharmacist Qualifying Examination Part I MCQ

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Canadian Pharmacy Regulatory Framework & Federal Legislation

1.1 Food and Drugs Act, Regulations, and Health Canada Oversight 1.2 Controlled Drugs and Substances Act (CDSA) & Controlled Substances Regulations (CSR) 1.3 NAPRA Drug Scheduling Framework & National Model Standards of Practice

2 Chapter 2: Ethics, Scope of Practice & Safety Culture

2.1 Professional Ethics, Fiduciary Duty & Health Information Privacy 2.2 Expanded Scope of Practice: Minor Ailments Prescribing, Renewals & Injections 2.3 Equity, Diversity, Inclusion, Cultural Safety & Continuous Quality Improvement

3 Chapter 3: Pharmaceutical Calculations & Posology

3.1 Concentrations, Dilutions, Alligations & Reconstitution 3.2 Dosing by Weight/BSA, Days Supply & Pediatric/Geriatric Dose Adjustments 3.3 IV Infusion Rates, Drop Factors, Osmolarity & Creatinine Clearance (Cockcroft-Gault)

4 Chapter 4: Compounding, Dispensing & Product Integrity

4.1 Non-Sterile Compounding & Beyond-Use Dating (NAPRA Standards) 4.2 Sterile Preparations & Hazardous Drug Handling (NAPRA / NIOSH Principles) 4.3 Prescription Verification, Auxiliary Labeling, Cold Chain & Medication Incident Prevention (ISMP Canada) 4.4 Dispensing Operations: Interchangeability, Adjudication, Compliance Packaging, Release & Inventory Control

5 Chapter 5: Clinical Pharmacology & Pharmacokinetics

5.1 Pharmacokinetic Principles: Clearance, Volume of Distribution, Half-life & Steady State 5.2 Cytochrome P450 Enzymes, Transporters & Significant Drug-Drug Interactions 5.3 Therapeutic Drug Monitoring (TDM), Narrow Therapeutic Index Drugs & Toxicities

6 Chapter 6: Evidence-Based Medicine & Literature Appraisal

6.1 Study Designs, Bias & Levels of Evidence in Clinical Research 6.2 Biostatistics: ARR, RRR, NNT, NNH, Confidence Intervals & P-values 6.3 Applying Canadian Practice Guidelines to Clinical Decision-Making 6.4 Drug Information Practice, Diagnostic Test Accuracy & Pharmacoeconomics

7 Chapter 7: Cardiovascular Pharmacotherapy: Hypertension, Dyslipidemia & CAD

7.1 Hypertension Management (Hypertension Canada Guidelines, Targets & Regimens) 7.2 Dyslipidemia & Atherosclerotic Cardiovascular Disease (CCS Guidelines & Statin Therapy) 7.3 Ischemic Heart Disease & Acute Coronary Syndromes (Antiplatelet & Antianginal Therapy)

8 Chapter 8: Cardiovascular Pharmacotherapy: Heart Failure, Arrhythmias & Anticoagulation

8.1 Heart Failure with Reduced & Preserved Ejection Fraction (GDMT & Monitoring) 8.2 Atrial Fibrillation, Arrhythmias & Rate vs. Rhythm Control 8.3 Venous Thromboembolism & Anticoagulation Therapy (DOACs, Warfarin & Thrombosis Canada)

9 Chapter 9: Endocrine & Metabolic Disorders

9.1 Type 2 Diabetes: Glycemic Targets, Non-Insulin Pharmacotherapy (Diabetes Canada) 9.2 Insulin Regimens, Type 1 Diabetes, Hypoglycemia & Diabetic Emergencies (DKA/HHS) 9.3 Thyroid Disorders & Osteoporosis (Diagnostic Parameters & Therapeutic Management)

10 Chapter 10: Respiratory & Gastrointestinal Disorders

10.1 Asthma Management & Exacerbations (CTS Guidelines, Relievers & Controllers) 10.2 Chronic Obstructive Pulmonary Disease (COPD) & Inhaler Delivery Systems 10.3 Gastroesophageal Reflux Disease (GERD), Peptic Ulcer Disease & GI Bleeding 10.4 Lower GI & Liver Disorders: Constipation, Diarrhea, IBS, IBD & Cirrhosis

11 Chapter 11: Infectious Diseases & Antimicrobial Stewardship

11.1 Respiratory Tract Infections: Otitis, Sinusitis, Pharyngitis, CAP & HAP 11.2 Urinary Tract, Skin/Soft Tissue & Sexually Transmitted Infections 11.3 Systemic Infections, Clostridioides difficile & Antimicrobial Stewardship Principles 11.4 HIV Prevention & Treatment, Viral Hepatitis, Tuberculosis & Fungal Infections

12 Chapter 12: Central Nervous System & Mental Health

12.1 Major Depressive Disorder & Anxiety Disorders (First-Line Agents & Safety) 12.2 Bipolar Disorder, Schizophrenia & Psychopharmacology Monitoring 12.3 Epilepsy, Seizure Types, Antiseizure Medications & Neuropathic Pain 12.4 Dementia, Parkinson Disease, Migraine, Insomnia & Restless Legs Syndrome

13 Chapter 13: Special Populations, Pain Management & Substance Use

13.1 Acute & Chronic Pain Management: Multimodal Analgesia & Opioid Stewardship 13.2 Substance Use Disorders: Opioid Agonist Therapy, Harm Reduction & Alcohol Withdrawal 13.3 Special Populations: Pharmacotherapy in Pregnancy, Lactation & Geriatrics (Deprescribing / Beers) 13.4 Palliative Care & Pediatric Pharmacotherapy

14 Chapter 14: Renal, Rheumatologic, Hematologic & Oncology Supportive Care

14.1 Chronic Kidney Disease, Acute Kidney Injury & Electrolyte Disorders 14.2 Osteoarthritis, Rheumatoid Arthritis & Gout 14.3 Anemias & Oncology Supportive Care

15 Chapter 15: Minor Ailments, Dermatology and Women's & Men's Health

15.1 Minor Ailments I: Allergic Rhinitis, Colds & Influenza, Eye and Ear Conditions 15.2 Minor Ailments II: Acne, Dermatitis, Psoriasis, Lice, Scabies & Sun Protection 15.3 Women's & Men's Health: Contraception, Emergency Contraception, Menopause, BPH, ED & Overactive Bladder

16 Chapter 16: Immunization & Health Promotion

16.1 Immunization Practice: NACI Recommendations, Administration, Cold Chain & Adverse Events 16.2 Health Promotion: Smoking Cessation, Weight Management, Screening & Social Determinants of Health

17 Chapter 17: Patient Care Process, Communication & Stewardship

17.1 The Patient Care Process: Assessment, Care Planning & Patient Interviewing 17.2 Patient Education, Device Counselling, Health Literacy & Overcoming Barriers 17.3 Interprofessional Collaboration, Pharmacy Workflow, Team Delegation & Drug Shortage Stewardship

2.2 Expanded Scope of Practice: Minor Ailments Prescribing, Renewals & Injections

Key Takeaways Explain This Topic AI

Pharmacist prescribing for minor ailments requires strict adherence to diagnostic boundaries, ensuring conditions are self-limiting and red flag symptoms (e.g., fever in suspected UTI, systemic rash, dysphagia in GERD) trigger immediate medical referral.

First-line empirical treatments for minor ailments must follow Canadian clinical guidelines, such as oral nitrofurantoin 100 mg BID for 5 days or fosfomycin 3 g single dose for uncomplicated cystitis, and single-dose oral doxycycline 200 mg within 72 hours for Lyme disease prophylaxis.

Prescription adaptation, therapeutic substitution, and renewal authorities permit pharmacists to optimize doses and extend chronic medications to safeguard continuity of care, and controlled-substance extensions need both provincial authority and the federal 2-year limit in section 101 of the Controlled Substances Regulations.

Injection authority authorizes intramuscular and subcutaneous routes for routine immunizations and therapeutics, mandating a minimum 15-minute observation period, ready access to intramuscular epinephrine (1:1000), and compliance with provincial minimum age thresholds.

Last updated: October 2026

Expanded Scope of Practice: Minor Ailments Prescribing, Renewals & Injections

The scope of pharmacy practice in Canada has undergone significant evolution, transforming pharmacists from medication dispensers into primary care providers with prescribing, adapting, renewing, and injection authorities. While provincial legislation governs the exact schedule of authorized conditions and procedural rules, standard principles of clinical assessment, diagnostic caution, and interprofessional communication apply nationwide.

1. Minor Ailments Prescribing Framework Across Canada

A minor ailment (often designated as a "common condition") is defined as a health condition that is:

Short-term and generally self-limiting;

Readily diagnosed through a structured patient interview and basic clinical assessment without requiring complex laboratory or diagnostic imaging procedures; and

Amenable to effective management with non-prescription drugs, Schedule I prescription pharmacotherapy, or non-pharmacologic interventions with minimal risk of masking an underlying serious disease.

Clinical Assessment & Care Process

When conducting a minor ailment assessment, the pharmacist must follow a rigorous, documented clinical process: PHARMACIST MINOR AILMENT ASSESSMENT FLOW

1. PATIENT PRESENTATION Establish identity, age, pregnancy/lactation status, and chief complaint.

  • │
  • ▼

2. CLINICAL INQUIRY Assess onset, duration, location, severity, and modifying factors (PQRST/SCHOLAR).

Review complete medical history, organ impairment, and current medication profile.

  • │
  • ▼

3. RED FLAG SCREENING Screen for high-risk exclusion criteria, systemic symptoms, and atypical features.

  • │
  • ┌───────────────┴───────────────┐
  • ▼ ▼
  • RED FLAGS PRESENT? NO RED FLAGS (SELF-LIMITING)
  • Immediate medical referral • Formulate therapeutic care plan:
  • Provide emergency first-aid - Non-pharmacologic measures
  • Communicate with physician - Schedule I prescribing / OTC selection
  • Educate patient on dosing & expected course
  • Document rationale & notify PCP within 24-48h
  • Schedule follow-up / safety net monitoring
  • Documentation and Interprofessional Notification

Prescribing a medication under minor ailment authority is an independent clinical act. The pharmacist must create a comprehensive clinical record containing:

  • Patient assessment details and clinical rationale for the chosen therapy;
  • Specific drug, dose, route, frequency, duration, and quantity prescribed;
  • Safety warnings and follow-up monitoring parameters; and

Written notification transmitted to the patient's primary care provider (PCP) within mandated provincial timeframes (typically within 24 to 48 hours), or a direct recommendation to the patient to share the record if they lack a family physician.

2. High-Yield Minor Ailments: Clinical Presentations, Treatments & Red Flags

The following table details the most heavily tested minor ailments in Canadian pharmacy examinations, contrasting first-line empirical treatments with critical red flags requiring physician referral:

Condition Typical Clinical Presentation First-Line Guideline Pharmacotherapy Critical Red Flags (Refer Immediately)

Uncomplicated Cystitis (UTI) Non-pregnant adult female; dysuria, urgency, urinary frequency, suprapubic discomfort; acute onset (<7 days). Nitrofurantoin 100 mg PO BID x 5 days (macrobid); Fosfomycin 3 g PO single dose sachet; TMP-SMX 1 DS tab PO BID x 3 days (only if local E. coli resistance <20%) Male patient (complicated by definition); Pregnancy; Fever (>38°C), chills, rigors, tachycardia; Flank pain / CVA tenderness, nausea/vomiting; Hematuria (gross), recurrent UTI (>2 in 6 mo / >3 in 1 yr); Immunocompromise, catheter-associated

Allergic Rhinitis Bilateral sneezing, clear watery rhinorrhea, nasal congestion, itching, conjunctivitis. Intranasal Corticosteroids (INCS): Fluticasone, mometasone, ciclesonide (first-line for moderate/severe); Second-generation oral antihistamines: Bilastine, cetirizine, fexofenadine, desloratadine Unilateral nasal symptoms, recurrent epistaxis; Purulent discharge, severe facial pressure/pain (sinusitis); Nasal polyps, structural deformities; Systemic fever, anosmia, visual changes

Herpes Simplex Labialis (Cold Sores) Prodromal tingling/burning followed by grouped fluid-filled vesicles on vermilion border; heals in 7–10 days. Oral Valacyclovir: 2000 mg PO BID x 1 day (12 h apart) taken at earliest prodrome; Topical Docosanol 10%: Applied 5 times daily at prodrome Lesions near or involving the eye/eyelid (herpes keratitis ophthalmic emergency); Immunocompromised state; Lesions lasting >14 days without resolution; Frequent recurrence (>6 episodes/year); Intraoral widespread ulcerations

Gastroesophageal Reflux Disease (GERD) Classic retrosternal burning (heartburn) and acid regurgitation; aggravated by recumbency or meals. H2-Receptor Antagonist (H2RA): Famotidine 20 mg PO daily or BID; Proton Pump Inhibitor (PPI): Pantoprazole 40 mg, esomeprazole 20 mg, or omeprazole 20 mg PO daily x 2–4 weeks ALARM features: Dysphagia, odynophagia; Unexplained weight loss, persistent vomiting; Evidence of GI bleeding (hematemesis, melena, anemia); New-onset dyspepsia in patients age >50 years; Non-response to 4-week trial of PPI

Superficial Bacterial Skin Infections (Impetigo) Non-bullous, erythematous lesions with classic "honey-colored" crusted erosions on face or extremities. Topical Mupirocin 2% ointment/cream TID x 5–7 days; Topical Fusidic Acid 2% cream/ointment TID x 7 days Widespread, systemic, or bullous lesions; Systemic signs: Fever, malaise, lymphadenopathy; Deep soft-tissue involvement, rapidly expanding erythema/warmth/pain (cellulitis); Lesions failing to respond within 48–72 hours

Hormonal Contraception Patient seeking initiation or restart of contraception; non-pregnant, seeking pregnancy prevention. Combined Hormonal Contraceptives (CHCs): Oral pills, transdermal patch, vaginal ring; Progestin-Only Pills (POPs): Norethindrone 0.35 mg daily or drospirenone 4 mg daily Blood pressure ≥140/90 mmHg (MEC 3/4); Migraine with aura (at any age - stroke risk); Age ≥35 and smoking ≥15 cigarettes/day; History of or active DVT/PE, thrombogenic mutation; Known or suspected active breast cancer

Lyme Disease Post-Exposure Prophylaxis Asymptomatic patient presenting following removal of an Ixodes blacklegged tick in an endemic area. Oral Doxycycline: 200 mg PO as a single dose (adults; 4.4 mg/kg up to 200 mg for pediatrics) with food and water Erythema migrans (expanding target rash ≥5 cm) present (indicates established Lyme disease -> full 10-14 day course); Systemic symptoms: Fever, arthralgia, facial palsy; Tick attached <24 hours or flat (non-engorged); Time from tick removal >72 hours

Caution

Single-dose doxycycline post-exposure prophylaxis (PEP) is only preventative; it is never appropriate for treating established Lyme disease. If an expanding erythema migrans rash (bull's-eye) or systemic manifestations are detected, the patient must be referred or prescribed a full 10- to 14-day therapeutic antimicrobial course.

3. Prescription Adaptation, Substitution & Renewals

In addition to initiating therapy for minor ailments, Canadian pharmacists exercise broad authority to adapt, substitute, and extend existing prescriptions to optimize patient outcomes and maintain continuity of care.

Prescription Adaptation

Prescription adaptation allows a pharmacist to alter an existing prescription issued by another authorized prescriber when clinically indicated:

Dosing Regimen & Formulation: Adjusting the dose, dosage form, frequency, or route of administration to improve adherence, accommodate swallowing difficulties (e.g., converting tablets to liquid), or account for altered renal function.

Missing Information: Completing missing elements (e.g., specifying dosage frequency when omitted) based on clinical evaluation and dialogue with the patient.

Substitution: Generic vs. Therapeutic

Generic Substitution (Interchangeability): Dispensing an interchangeable generic bioequivalent drug in place of the prescribed brand-name product in accordance with provincial drug formulary interchangeability tables. Pharmacists must adhere to patient choice and respect legitimate "no substitution" orders.

Therapeutic Substitution: Substituting a prescribed drug with a chemically distinct medication within the same therapeutic or pharmacological class (e.g., substituting an alternative ACE inhibitor during a drug shortage, or switching an ARB based on regional formulary coverage). Therapeutic substitution authority exists in select jurisdictions (e.g., British Columbia, Alberta) under established clinical protocols.

Renewals (Prescription Extensions)

Pharmacists may renew existing prescriptions for chronic, stable conditions to prevent treatment interruption when a patient is unable to access their primary prescriber:

Eligibility: The patient must have a chronic, stable medical condition and have demonstrated safe, long-term tolerance of the drug.

Duration Limits: Renewals are generally limited to the duration of the original prescription or a maximum quantity of 6 to 12 months depending on provincial regulations.

Controlled substances: From 2020 to September 30, 2026, pharmacists could extend controlled-substance prescriptions only under a temporary federal subsection 56(1) class exemption. Since October 1, 2026, section 101 of the Controlled Substances Regulations allows a pharmacist to extend one if provincial law authorizes renewals. The new expiry date can be no later than 2 years after the pharmacy received the prescription. Provincial rules and college standards may still exclude some drugs (for example, opioids or benzodiazepines) from pharmacist renewal, and the stricter rule applies.

4. Injection Authority & Anaphylaxis Management

Pharmacist authorization to administer medications by injection is established across all Canadian provinces, expanding immunization coverage and medication delivery.

Authorized Routes and Anatomic Sites

Intramuscular (IM): Administered at a 90° angle into muscle tissue. Preferred sites:

Deltoid Muscle: Upper outer arm, 2–3 finger-breadths below the acromion process (primary site for adults and older children).

Vastus Lateralis: Anterolateral thigh (preferred site for infants and toddlers under 12 months).

Subcutaneous (SC): Administered at a 45° or 90° angle (depending on needle length) into adipose tissue. Preferred sites include the anterolateral thigh, abdomen (avoiding 2 inches around the umbilicus), and the outer aspect of the upper arm.

Prohibited Route: Intravenous (IV) injection is strictly outside the authorized scope of community pharmacist practice in Canada.

Age Thresholds & Regulatory Protocols

Age thresholds for pharmacist-administered injections vary by province, by product, and over time:

For seasonal influenza vaccines, some provinces let pharmacists vaccinate children from about age 2, while others set a higher minimum age (often 5 years or older).

Other vaccines and injectable medications (for example travel vaccines, HPV, vitamin B12, or denosumab) can have different age limits and may require a prescription or additional training.

Check the current provincial regulation or college standard before vaccinating a young child; exam items give the rule in the stem when a provincial age limit matters.

Acute Management of Anaphylaxis

Anaphylaxis is a severe, rapid-onset, life-threatening systemic hypersensitivity reaction. Pharmacists administering injections must maintain current Basic Life Support (BLS/CPR) certification, have immediate access to an in-date emergency anaphylaxis kit, and observe every patient for a minimum of 15 minutes post-injection (extended to 30 minutes for patients with a history of severe allergies). ANAPHYLAXIS EMERGENCY RESPONSE

1. RECOGNITION Identify acute respiratory distress (stridor, wheezing, dyspnea),

hypotension/shock, diffuse urticaria, angioedema, or gastrointestinal cramps.

  • │
  • ▼
  • 2. FIRST-LINE DRUG IMMEDIATELY inject Epinephrine 1:1000 (1 mg/mL) INTRAMUSCULARLY

into the anterolateral aspect of the mid-thigh (vastus lateralis).

  • Adult dose: 0.3 mg to 0.5 mg IM
  • Pediatric dose: 0.01 mg/kg IM (max 0.3 mg)
  • │
  • ▼

3. POSITIONING & EMS Call 911 / emergency medical services immediately.

Place patient SUPINE with legs elevated (unless breathing is compromised;

if vomiting/pregnant, position on left side). Never stand or walk the patient.

  • │
  • ▼

4. REPEAT DOSING Repeat IM Epinephrine every 5 to 15 minutes if symptoms persist or deteriorate.

Adjunctive oral/IV antihistamines or corticosteroids must NEVER delay epinephrine.

5. Laboratory Test Ordering & Interpretation Rights

In several Canadian provinces (Alberta was the first to grant it broadly), pharmacists possess the statutory authority to order, receive, and interpret laboratory tests to support pharmacotherapy management.

Clinical Indications: Monitoring therapeutic drug levels (e.g., digoxin, lithium, phenytoin, aminoglycosides), assessing organ function prior to dosage adjustment (e.g., serum creatinine and eGFR for DOACs, metformin, and renally cleared antimicrobials), monitoring international normalized ratio (INR) for warfarin therapy, and checking metabolic parameters (HbA1c, fasting glucose, lipid panels, electrolytes).

Legal Responsibility: When ordering a laboratory test, the pharmacist assumes complete clinical and legal responsibility for reviewing the result, acting upon abnormal values, communicating critical findings to the patient and primary physician, and documenting the follow-up plan.